Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Taylor & Francis Group
2017-08-01
|
| Series: | Journal of Dermatological Treatment |
| Online Access: | http://dx.doi.org/10.1080/09546634.2017.1307464 |